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Abstract
Background: The cost effectiveness of inhaled TOBI tobramycin nebuliser solution (TNS) in CF and chronic pulmonaryR
Pseudomonas aeruginosa infection has been shown in US but not in European studies. Methods: An economic evaluation of TNS
was undertaken in children and adults. Lung function and resource utilisation were recorded for 24 months before and during
TNS therapy. Interventions were costed. Results: Forty-one patients received TNS; 30 of them matched with a paired control on
usual therapy. TNS cases received more inhaled and IV antibiotics in the year before TNS than controls, and were hospitalised
more. In the TNS treated group mean days in hospital before and after (change) were 32.0, 24.2 (y7.8); days on IV antibiotics
55.4, 38.9 (y16.4); total cost £22 102, £28 394 (q£6292), composed of cost of TNS £0, £10 010 (q£10 010), cost of
hospitalisation £10 897, £8552 (y£2345), cost of drugs £11 205, £9832 (y£1374). In 19 patients aged -18 the change in days
hospitalised was y10.7 and days on IVs y20.2. Incremental cost was £3830. Conclusions: TNS was associated with clinically
and socially important reductions of hospital attendances and parenteral antibiotics. This would improve patients’ quality of life
and reduce interference with work and schooling. Its maximal acquisition cost of £10 010 may be reduced by delays in prescribing
and dispensing, and was offset by savings of approximately £3500–6200.
 2003 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
As patients with cystic fibrosis (CF) reach adoles-
cence, chronic respiratory infections occur, and P. aeru-
ginosa becomes the dominant pathogen w1x. Chronic
infection due to P. aeruginosa provokes a persistent
inflammatory response, and is associated with progres-
sive deterioration in lung function in adolescents and
young adults w2,3x. Once P. aeruginosa is established, it
is very difficult to eradicate, and despite current standard
therapy, lung function continues to decline at a rate of
approximately 2% per year w4x. The traditional treatment
of chronic P. aeruginosa infection has been to administer
parenteral antibiotics especially during exacerbations.
However, administration of drug by inhalation is now
widely used to deliver high concentrations directly to
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the site of infection, and at the same time minimise
systemic toxicity w5,6x. Accordingly, practice in both the
UK and USA is now to give long-term suppressive
inhaled therapy.
The antipseudomonal aminoglycoside tobramycin has
been extensively investigated for delivery as an aerosol.
A tobramycin solution has been developed specifically
for use by inhalation that is sterile, non-pyrogenic and
preservative free. This is registered in the UK as
TOBI 300 mgy5 ml nebuliser solution (tobramycin)
(TNS) for the treatment of chronic pulmonary P. aeru-
ginosa infection in patients aged 6 years or older. In a
financially-constrained health service, it is often neces-
sary to demonstrate the cost-effectiveness of healthcare
interventions. Many new pharmaceutical products, spe-
cifically designed to treat a given disease, are more
expensive than the older treatments they replace and
there is a need to generate evidence on their value for
money. Cost offsets may occur through changes in
overall patient management with a reduction in the use
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of other healthcare resources. Economic evaluations
compare the costs and benefits of treatments and pro-
grammes. They can be conducted alongside clinical
trials or observational studies, the latter having the
advantage that they better reflect actual clinical practice.
The present study was designed to investigate in a
British population the impact of TNS on usage of costly
healthcare resources that have a high consumption in
CF.
2. Materials and methods
The study set out to compare utilisation of specified
healthcare resources over two 1 year periods before and
during treatment with TNS in patients with CF. An
observational design was chosen because randomised
clinical trial (RCT) data on the clinical and resource
impact of TNS already existed. It was felt important to
reflect actual clinical practice in the UK. The traditional
measures of medium term clinical benefit were analysed:
lung function as judged by FEV % predicted, and body1
weight expressed as standard deviations from the mean.
Other interventions and medication taken on and off the
study treatment were recorded. By costing these the net
financial effect of TNS treatment could be calculated,
and a cost-effectiveness analysis was undertaken. Con-
clusions were drawn for the population as a whole and
also for a pre-determined subgroup of patients below
the age of 18. Patients who had received TNS were
matched at the time of the start of TNS treatment to
individual patients who had not had this therapy, accord-
ing to age (within "6 months), gender, lung function
(within "20% FEV % predicted) and chronic infection1
with P. aeruginosa. Matching was undertaken within the
same CF clinic to avoid confounding by differences in
care.
Specialised CF centres known to prescribe TNS were
invited to take part. An attempt was made to include
centres in different regions, and to achieve a balance
between paediatric and adult patients. Patients were
included in whom the diagnosis of CF had been previ-
ously confirmed by standard tests. In this survey chronic
infection was defined as the presence of P. aeruginosa
in a sputumythroat culture on two occasions over six
months during the year prior to and on one occasion
following the start of TNS. The recommended dose of
TNS is 1 ampoule of 300 mg tobramycin in 5 ml,
nebulised twice daily for 28 days. The dosage interval
should be as close as possible to 12 h, and not less than
6 h. After 28 days of therapy subjects stop therapy for
the next 28 days. Patients who had not been treated
with TNS broadly in accordance with the SmPC for the
product, or in whom fewer than 2 cycles (4 months in
total) had been administered, were excluded. Data on
patients in whom either period was 28"4 days (i.e.
24–32 days) were accepted. Twelve of the study patients
had previously taken part in a short-term trial to compare
TNS with colistin w7x.
The protocol and other study documentation were
approved by Multicentre and Local Research Ethics
Committees. Patients andyor their parents or guardians
gave fully informed consent to participation, and data
handling was carried out according to the Data Directive.
TOBI has a Product Licence in the UK (PL 17092y
0002).
All assessments of FEV % predicted made over the1
years before and during TNS treatment were extracted
from the patients’ medical records provided that the
patient was infected at the time with P. aeruginosa, and
that valid assessments were made, e.g. by a physician
or trained technician. Values were standardised as
FEV % predicted scores using the Knudson equation1
w8x. Bodyweight data were also recorded for the above
time periods and expressed as standard deviations w9x.
Serial measures of both FEV % predicted and body-1
weight standard deviation scores were reduced to an
average value for the year before treatment and the year
during treatment using the summary statistic of area
under curve.
A key measure of interest in a cost effectiveness
analysis is the numbers of days in hospital, since these
are very expensive and may be expected both to degrade
quality of life and reduce patients’ educational possibil-
ities or capacity for wage earning. Use of intravenous
antibiotics, whether at home or during an admission,
reflects acute infective pulmonary exacerbations. These
might be avoided by effective maintenance antibiotic
therapy. Other healthcare interventions that were record-
ed were: intercurrent illnesses and surgical procedures
(to ensure that other significant occurrences did not
make it invalid to draw conclusions from the data);
medication (drug, dosage regime, dates) including that
prescribed for CF or for any other intercurrent illness
but excluding such drugs as vitamins and pancreatic
enzyme supplements that would be given at unchanged
dosage over long periods; both routine and urgent out-
patient attendances; in-patient stays (total stay annual
duration, number of admissions and reasons); ICU
admissions (duration, number and reasons).
The year 2001 unit costs (prices) of ward and ICU
stays (Table 1) were ascertained using routinely availa-
ble National Health Service reference data w10x since
these were more generalisable and easier to obtain than
local costs. This enabled hospitalisation costs to be
calculated for each patient for the year before and after
starting TNS therapy.
For each TNS patient, the change in average value of
an outcome from the year before treatment to the year
during treatment was calculated. Analyses within the
TNS group employed this change as the outcome.
For each TNS patient who had a matched control, the
difference between the change in the TNS patient and
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Table 1
Costs of interventions
Healthcare resource Unit cost £ sterling Notes
Hospitalisation day 313.15 Mean of values for general
medical paediatric and
adult beds*
ICU day 1275
Probably underestimates costs of ward care of CF patients.*
Table 2
Patient characteristics
TNS Control TNS
matched patients matched patients all patients*
ns30 ns30 ns41
Sex
Male 15 (50%) 15 (50%) 21 (51%)
Female 15 (50%) 15 (50%) 20 (49%)
Age (yrs)
6.0 to12.9 6 (20%) 7 (23%) 8 (19%)
13.0 to17.9 8 (27%) 6 (20%) 11 (27%)
18.0 and over 16 (53%) 17 (57%) 22 (54%)
Range 7.9 to 36.6 8.13 to 33.7 7.9 to 37.4
Previous inhaled antibiotic
No 10 (33%) 14 (47%) 12 (29%)
Yes 20 (67%) 16 (53%) 29 (71%)
FEV % predicted1
80.0 and over 5 (17%) 5 (5%) 8 (20%)
40.0 to 79.9 14 (47%) 17 (68%) 19 (46%)
25.0 to 39.9 10 (33%) 5 (17%) 11 (27%)
less than 25.0 1 (3%) 3 (10%) 3 (7%)
Including 11 patients treated with TNS for whom it was not pos-*
sible to find matched pairs.
the corresponding change in the control was calculated
and referred to as the net effect. The matched analyses
employed the net effect as the outcome. Results were
reported as means with accompanying 95% confidence
intervals that were obtained using the Non-parametric
Bootstrap Bca method w11,12x, which is a resampling
method that does not require data to have a normal
population distribution. These methods were used for
both effectiveness and cost measures w13x. Where hos-
pitalisations, IV, or cost outcomes were available for
less than the one-year period, the measures were scaled
up to one year on a pro-rata basis. Pre-planned sub-
groups were age below 18 years, age 18 years and over,
prior treatment with inhaled antibiotics, and no prior
inhaled antibiotics. Cost data, together with the meas-
urements of clinical efficacy, were used to assess the
cost-effectiveness of TNS therapy in this population.
3. Results
Eight centres participated; recruiting a total of 71
patients into the study. There were 41 TNS treated
patients. Thirty of these could be matched according to
chronic P. aeruginosa infection, gender, age and FEV %1
predicted with a paired case within the centre who had
not received TNS. The demography of all the patients
is summarised in Table 2.
The TNS and Control groups’ genders, ages and
FEV % predicted (mean 56.3 vs. 57.4 over the pre-TNS1
period), were well matched. However, there was an
imbalance in the prior use of inhaled antibiotics, with
29 (71%) of the full TNS group of 41 patients receiving
these agents compared to 16 (53%) of the 30 controls.
A somewhat surprising finding was the degree to which
patients being treated with TNS in the second time
period also received inhaled colistin in the alternating
months off tobramycin: 20 (49%) of the 41 TNS treated
patients.
Table 3 shows the clinical outcomes and healthcare
resource utilisation in the TNS treated patients and
matched controls.
There was again evidence of imbalance between the
TNS and matched control groups. The mean numbers
of days of hospitalisation (including general ward as
well as ICU admissions) for the year before the start of
TNS were 32.1 and 27.0 days for the treatment and
control groups, respectively. The equivalent figures for
the mean numbers of days of intravenous antibiotic
treatment were 57.6 and 33.6 days.
Mean FEV % predicted fell slightly more in the1
control group over the study period than in the TNS
group (1.63 vs. 1.36). There was a slightly larger
increase of weight S.D.s in the TNS group (0.12 vs.
0.03). Neither of these changes was statistically signif-
icant. There was a similar reduction in the mean total
number of days of hospitalisation in the TNS and control
groups, although the figure for the control group before
treatment was considerably increased by an outlier who
was an inpatient because of a pulmonary exacerbation
for most of the period for which he was studied before
the period that corresponded to TNS treatment of his
matched pair. There was a reduction of 24.1 days of
intravenous antibiotic treatment in the TNS group with
no change in the controls, and this difference was
statistically highly significant (P-0.001).
As the treatment and control groups were so unbal-
anced in respect of pre-treatment admissions and anti-
biotic use the main analysis was of the larger group of
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Table 3
Clinical outcomes and resource utilisation-matched pairs-means
Matched pairs n pairs Year Year Change Net Effect (95% CI)
Pre Post Post-Pre TNS change–Control change
FEV % predicted1 30
TNS 56.3 54.9 y1.36 q0.27 (y2.86 to q3.40)
Control 57.4 55.8 y1.63
Weight S.D. Score 27
TNS y1.16 y1.05 q0.12 q0.09 (y0.18 to q0.32)
Control y1.27 y1.24 q0.03
Days in hospital 30
TNS 32.1 21.6 y10.5 q2.4 (y10.6 to q33.3)
Control 27.0 14.1 y12.9
Length of IVs (days) 30
TNS 57.6 33.5 y24.1 y23.3 (y37.6 to y11.4)
Control 33.6 32.9 y0.8
Clinics (number) 30
TNS 10.8 8.1 y2.66 y1.46 (y5.86 to q1.79)
Control 9.7 8.5 y1.20
OP Visits (number) 30
TNS 0.9 0.7 y0.23 y0.42 (y1.33 to q0.07)
Control 0.2 0.4 q0.19
IV courses 30
TNS 3.6 2.3 y1.27 y1.27 (y2.28 to y0.34)
Control 2.3 2.3 q0.00
Ward admissions 30
TNS 2.9 2.0 y0.94 y0.34 (y1.31 to q0.58)
Control 2.1 1.5 y0.59
ICU admissions 30
TNS 0.2 0.2 q0.07 q0.08 (y0.27 to 0.53)
Control 0.1 0.1 y0.01
41 TNS treated patients comparing data 12 months
before and 12 months during the use of TNS (Table 4).
In this group of patients FEV % predicted declined1
by 1.26 (n.s.) and weight S.D. score rose by 0.07 (n.s.)
in association with TNS treatment. There was a reduc-
tion of 7.8 in the mean number of days spent in hospital
(24%), resulting in a saving of £2345. There was a
mean reduction of 16.4 days on intravenous antibiotics
(30%), and the mean total saving in costs of antibiotics
including those given intravenously was £1344. CF
clinic attendances fell from a mean of nearly 10 per
year to just under eight (20%). Admissions to the ward
were reduced from an average of three per year to just
over two (28%). The mean number of courses of IV
antibiotic treatment fell from approximately three and a
half per year to two and a half (27%). The overall
saving of drug costs was £1374. Thus, the cost of
purchasing TNS in the second period was offset by
£3719, mainly by reductions in ward and antibiotic
costs, giving a net cost £6292 per annum. Fig. 1 shows
the overall costs for the patients before and during TNS
treatment, as well as their components.
Table 5 shows the ten most expensive antibiotics used
by all patients in this study in the year before the start
of TNS treatment, the total cost of each one for the
whole group and the average yearly cost per patient.
Previous trials of TNS have shown larger clinical
effects in adolescents, and analysis of the subgroup of
patients aged 18 years and younger was planned in this
study: Table 6.
In this smaller subset of 19 TNS treated patients
FEV % predicted rose by 0.19 in association with1
therapy (ns) and weight S.D. score rose by 0.06 (ns).
Days spent in hospital were reduced by an average of
28%, resulting in mean savings of £4458; and mean
antibiotic costs diminished by £1744. There were reduc-
tions of 37% in numbers of CF clinic attendances, 48%
in numbers of outpatient visits, 37% in days of IV
therapy, 40% in numbers of IV courses and 23% in
ward admissions. The acquisition cost of a year’s TNS
was offset by £6180 in this group giving a net cost of
£3830. Fig. 2 shows the cost components for this
subgroup.
4. Discussion
A review of published economic and quality of life
studies in cystic fibrosis identified 58, of which 12 were
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Table 4
Analysis within TNS treated group
n* Pre Post Change (Post minus Pre)
Mean Mean Mean (95% CI)
Clinical outcomes
FEV % predicted1 41 56.2 54.9 y1.26 (y3.34 to q0.83)
Weight SD Score 39 y1.15 y1.07 q0.07 (y0.08 to q0.23)
Days in hospital 41 32.0 24.2 y7.8 (y13.0 to y3.2)
Length IVs (days) 41 55.4 38.9 y16.4 (y27.4 to y7.9)
Clinics (number) 41 9.9 7.9 y1.95 (y5.43 to y0.29)
OP visits (number) 41 1.2 1.2 0 (y0.66 to q0.85)
IV courses 41 3.6 2.6 y0.98 (y1.71 to y0.45)
Ward admissions 41 3.0 2.2 y0.83 (y1.52 to y0.32)
ICU admissions 41 0.1 0.2 q0.05 (y0.20 to q0.59)
Costs
Total cost £ 41 22 102 28 394 q6292 (q3138 to q9193)
Cost components:
TNS Cost 41 0 10 010 q10 010 (q10 010 to q10 010)
Hospitalisation Cost 41 10 897 8552 y2345 (y4932 to q120)
Drug Cost 41 11 205 9832 y1374 (y3184 to y33)
Drug cost components:
Antibiotics Cost 41 6716 5373 y1344 (y3296 to y97)
Other Drug Cost 41 4489 4459 y30 (y185 to q124)
Hospitalisation cost
components:
Ward Cost 41 9715 7246 y2469 (y4564 to y914)
ICU Costs 41 1182 1306 q124 (y2052 to q4634)
n for specified data.*
Fig. 1. Components of Cost TNS Patients, ns41.
full economic evaluations. There was a wide geograph-
ical spread of studies, with an increasing number in
recent years. The topics studied included rhDNase, home
vs. hospital IV antibiotics and other named drugs. The
main economic findings were that (i) the annual costs
of care for CF vary greatly with disease severity; (ii)
hospitalisations account for the greatest portion of costs
for CF patients; and (iii) the costs of expensive therapies
may be partly offset by savings in other resources.
TNS has been studied in 520 patients also receiving
standard therapy in two identical multi-centre, random-
ised, double blind trials in the USA w4x leading to a
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Table 5
Ten highest cost antimicrobials pre-TNS ns71
Drug Route Total cost £ Cost per patient £
Meropenem IV 112 268 1581
Ceftazidime (Fortum) IV 100 027 1409
Ceftazidime (Kefadime) IV 8494 120
Colomycin (Colistin) Inhaled 49 475 697
Tobramycin IV 38 892 548
Aztreonam (Azactam) IV 16 591 234
Piperacillin (Tazocin) IV 12 348 174
Flucloxacillin Oral 8512 120
Gentamicin Inhaled 5316 75
Tobramycin Inhaled 4927 69
Table 6
Analysis within TNS treated group–patients less than 18 years
n Pre Post Change (Post minus Pre)
Mean Mean Mean (95% CI)
Clinical outcomes
FEV % predicted1 19 64.8 65.0 q0.19 (y3.44 to q3.82)
Weight SD Score 19 y0.73 y0.67 q0.06 (y0.13 to q0.25)
Days in hospital 19 38.5 27.8 y10.7 (y16.7 to y5.8)
Length IVs (days) 19 54.8 34.6 y20.2 (y39.3 to y8.8)
Clinics (number) 19 9.5 5.9 y3.53 (y10.74 to y0.63)
OP visits (number) 19 2.1 1.1 y1.00 (y2.11 to y0.11)
IV courses 19 4.1 2.5 y1.63 (y2.95 to y0.89)
Ward admissions 19 3.6 2.8 y0.82 (y1.74 to y0.26)
ICU admissions 19 0.1 0.1 y0.05 (y0.53 to q0.05)
Costs
Total cost £ 19 24 250 28 080 q3830 (y1165 to q6805)
Cost components:
TNS Cost 19 0 10 010 q10 010 (q10 010 to q10 010)
Hospitalisation Cost 19 13 228 8769 y4459 (y9436 to y2317)
Drugs Cost 19 11 022 9301 y1721(y5054 to y102)
Drug cost components:
Antibiotics Cost 19 5827 4082 y1744 (y5127 to y103)
Other Drug Cost 19 5195 5219 q24 (y197 to q363)
Hospitalisation cost
components:
Ward Cost 19 11 685 8702 y2983 (y4928 to y1549)
ICU Costs 19 1543 67 y1476 (y9261 to q67)
pooled analysis. TNS, administered for 24 weeks in
cycles of 28 days on and then 28 days off, was compared
with placebo. TNS improved pulmonary function and
decreased the density of P. aeruginosa in the sputum.
Patients on TNS were 36% less likely to require intra-
venous antipseudomonal antibiotics than those in the
placebo group. They were also 26% less likely to require
hospitalisation. These improvements were seen in all
patients, although the greatest effect was in those aged
13–17 years. Weight at 6 months had increased in the
tobramycin-treated adolescent patients by 1.3 kg more
than in the adolescents receiving placebo (Ps0.008).
The reductions in the need for both intravenous antip-
seudomonal antibiotic therapy and hospitalisation were
maintained in an open extension of the study in which
396 patients continued on treatment for up to 96 weeks
in total w14x. A further open parallel group study
conducted in the UK compared TNS with aerosolised
colistin sulfomethate (Colomycin ), in 115 patients with
CF and chronic P. aeruginosa infection w7x. Over the
28-day treatment period TNS significantly improved
lung function, and whilst both drugs decreased sputum
P. aeruginosa counts, the greater benefit was seen in the
TNS group.
Although TNS has been more extensively studied in
RCTs than any other antibiotic used to treat respiratory
infection in CF, it has not been previously subjected to
an economic evaluation in European clinical practice. In
the previous North American studies, hospitalisations
and the use of intravenous antibiotics were reduced by
the TNS regimen, but most US study patients had not
previously received inhaled antibiotics. In Europe CF
patients chronically infected with P. aeruginosa will
normally take inhaled antibiotics such as Colistin for
long periods. Additionally, the US healthcare setting and
method of funding are very different from those in
Europe. An observational survey was the most appro-
priate design to use to gather health economic data on
this new therapy. A prospective randomised controlled
trial answers a specific scientific question in a somewhat
artificial setting. This approach is necessary to control
bias and other confounding influences. A survey of cost
effectiveness in a naturalistic setting assesses the cost
that was associated with achieving specified clinical
outcomes in real life use of the drug. Both kinds of
evidence are necessary fully to inform clinical and
managerial decision making.
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Fig. 2. Components of Cost TNS Patients -18, ns19.
It did not prove possible to find matches according
to the defined criteria for 11 of the 41 TNS treated
patients. Cystic fibrosis is a rare disease and it is likely
that in a centre where this medication was in use most
patients with similar characteristics were treated with
the drug, and so were not eligible for matching. Even
when 30 P. aeruginosa infected patients adequately pair-
matched for gender, age and FEV % predicted were1
found they proved on analysis to have received fewer
inhaled antibiotics in the year before the TNS treatment
period. (Surprisingly, since this is contrary to accepted
guidelines w15x, only two thirds of all 71 patients studied
had been previously treated with inhaled antibiotics.)
The control patients also had substantially lower rates
of hospital admission and use of IV antibiotics. It is
likely, therefore, that the patients subsequently treated
with TNS were undergoing more frequent pulmonary
exacerbations, and this suggests that the occurrence of
exacerbations influenced prescribing more than the level
of FEV % predicted. Any bias in clinical response would1
tend to count against TNS in this situation since the
severe case already being treated with an inhaled anti-
biotic might be less likely to respond to another one.
The high rate of use of alternating inhaled TNS and
colistin in this study during the second time period also
shows that the TNS patients were relatively severely
affected cases. Sicker patients may not tolerate 28 days
off inhaled antibiotics.
The matched pairs analysis showed that mean FEV %1
predicted fell slightly more in the control group over
the study period than in the TNS group (1.63% vs.
1.36%) despite the greater severity of disease in the
TNS group. FEV % predicted is a good predictor of1
mortality in CF. After adjusting for age and gender, the
relative risk of death doubles with each 10% loss of
FEV % predicted w16x. A reduction of decline rate in1
lung function is of considerable clinical importance as
even small changes in the annual rate may well prolong
life by worthwhile amounts.
It proved next to impossible to ascertain the local
costs of the healthcare interventions recorded in this
study, and so national data were used (Table 1). The
lack of ready availability of cost data in CF clinics was
unexpected given the UK health service’s emphasis on
cost effectiveness. The drug costs were not adjusted
according to any discounts that might be obtained locally
since these are regarded as confidential by the institu-
tions in question. However, since the data on resource
utilisation, such as days of IV therapy or clinic atten-
dances are provided here local savings can be computed
as required. It may be felt that a saving of days in
hospital does not bring a financial benefit since the
vacant bed will be quickly filled by another patient. As
clinical services are increasingly purchased by external
consortia such as primary care trusts real budgetary
savings will occur, and the reduction in the length of
the waiting list is valuable.
The ideal new treatment would be associated with
both cost reduction and enhanced clinical benefit,
although this is rarely possible. In the whole group of
41 patients treated with TNS the incremental cost in the
year on treatment, taking account of the cost offsets
from savings of £2345 for hospitalisation and £1374
from drugs, was £6292. This equates to £17.24 per day.
For reasons of practicality not all interventions and
social consequences were recorded in this survey; such
as use of oxygen, laboratory tests, imaging, community
care, patient and family expenses and loss of education
and work. Additionally, the reductions in clinic and
outpatient attendances were not costed. The figure used
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for the cost of an overnight hospital stay was one for
general rather than CF wards. If all these factors were
taken into account the savings from use of TNS would
have been higher. The acquisition cost for TNS used
was the theoretical annual maximum of £10 010. The
actual amount was likely to have been less. Failure to
prescribe prophylactic therapy in the long term as is
necessary has been identified in paediatric asthma by
Warner w17x. It is probably a feature of many chronic
diseases, and may be expected to occur more for unusual
dose schedules where timing is critical, such as the
cyclical 28 days on and off required for TNS. A further
factor is the hiatus that may occur when prescribing is
handed over from a hospital based specialist to a
community based doctor. Additionally, the communica-
tion process between physician and parent or patient
may be suboptimal so that neither is aware of the
doctor’s recommendations w18x. Finally, prescriptions
may be dispensed later than intended, or not at all.
The survey 10 years ago w19x of the total cost of care
of CF patients in various bands of severity gave annu-
alised figures of £2792–£19 955. Reporting data gath-
ered in The Netherlands in 1990–1991 Wildhagen et al.
w20x found an average cost of care of £10 908. Little-
wood and Cross w21x presented paediatric data (age 5
years onwards) gathered in Leeds in 1996. Depending
on age and severity their annual costs averaged between
£3632 and £33 912. Allowing for inflation these findings
are in broad agreement with the present study. Here the
average costs of the specified interventions in the year
before TNS (ns41) were £22 102 for this moderately
affected group. Inhaled therapy contributes significantly
to cost of care in CF. However, from Table 5, the very
substantial cost contribution that intravenous antibiotic
therapy also makes can be seen. For the six most
expensive IV agents alone the cost of a year’s treatments
for all 71 patients was £288 622 (£4065 per patient).
This underlines the financial benefit of avoiding this
form of therapy where possible.
TNS use was associated with a reduction of 7.8 days
(24.3%) in hospital and of 16.4 days (29.6%) on
intravenous antibiotics. These two measures are good
surrogates for pulmonary exacerbations. Such exacer-
bations are important as they are associated with quan-
tum declines in lung function w22x. They are often the
terminal event. At any stage in a patient’s life they are
distressing for the patient, carers and clinical staff alike.
Britto et al. w23x have showed the association that exists
between reductions in Health Related Quality of Life
scores and both the number of exacerbations in the
previous 6 months and the number of days since the
last exacerbation. As their treatment usually involves
inpatient admissions they interfere with schooling, work
and social contacts. Even home treatment reduces mobil-
ity, which is particular unwelcome to teenagers. For the
patient with CF, avoidance of treatment with intravenous
therapy is an important goal in its own right as it may
give rise to unpleasant side effects.
In the TNS group analysis of 19 patients aged less
than 18 the reductions of hospitalisation and IV days
per year were 10.7 (27.7%) and 20.2 (36.9%), respec-
tively: achieved at an incremental cost of £10.49 per
day. Subgroup analyses in trials of TNS in the US w24x
and UK w7x suggested greater clinical benefit in younger
patients, and the current study confirms this. There is
an apparent tendency for use of TNS within the UK
National Health Service to be reserved for patients who
are more severely affected. Not unexpectedly many of
these are older patients. This study suggests that this
policy should be reviewed. In younger patients frequent
admissions for exacerbations are probably not yet occur-
ring, but de Jong et al have recently w25x pointed out
that ‘what is lost is lost’. That is: lung function declines
in Pseudomonas colonised cystic fibrotics are at least
partially irreversible and should as far as possible be
avoided rather than simply treated. Moss feels w24x that
it would be wrong to sacrifice demonstrable present
gains because of concerns about theoretical future dis-
advantages. ‘Withholding long-term inhaled tobramycin
therapy to preserve the effectiveness of IV antibiotics
may present risks even greater than those posed by
decreased antibiotic susceptibility’.
Use of inhaled TNS for 12 months in the study
population of moderately severely affected CF patients
gave rise to important clinical and social benefits such
as reduction of hospitalisation and the use of intravenous
antibiotics, which would be expected to improve
patients’ quality of life as well as to reduce interference
with work and schooling. Its acquisition cost was par-
tially offset by the savings that occurred in these
expensive components of patient care.
Acknowledgments
The Pharmacoeconomics Study Group comprised:
Richard Iles and Julia Legh-Smith, Addenbrooke’s Hos-
pital, Cambridge, Diana Bilton and Elaine Gunn, Pap-
worth Hospital, Alastair Reid and Anne-Marie Watson,
Belfast Childrens Hospital, Ronald Knight and Jackie
Hext, Frimley Park Hospital, Stuart Elborn and Julie
Kapur, Royal Belfast Hospital, Steve Conway, Seacroft
Hospital, Leeds, Christopher Taylor and Jean McGaw,
Sheffield Childrens Hospital, Gary Connett and Judi
Maddison, Southampton General Hospital, Toby Prevost
and Sarah Vowler, Centre for Applied Medical Statistics,
Cambridge, Paul Marcus and Veronica Englishby, Mar-
cus Ridley Associates Ltd., Michael Drummond, Marco
Barbieri and Jeremy Chancellor, Innovus Research (UK)
Ltd.
References
w1x Fitzsimmons SC. The changing epidemiology of cystic fibrosis.
J Pediatr 1993;122:1–9.
128 R. Iles et al. / Journal of Cystic Fibrosis 2 (2003) 120–128
w2x Denton M, Wilcox MH. Antimicrobial treatment of pulmonary
colonization and infection by Pseudomonas aeruginosa in
cystic fibrosis patients. J Antimicrob Chemother 1997;40:468–
74.
w3x Govan JRW, Deretic V. Microbial pathogenesis in cystic
fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia
cepacia. Microb Rev 1996;60(3):539–74.
w4x Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB,
Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM,
Marshall BC, Marshall S, Smith AL. Intermittent administra-
tion of inhaled tobramycin in patients with cystic fibrosis. N
Eng J Med 1999;340(1):23–30.
w5x Hodson ME, Penketh AR, Batten JC. Aerosol carbenicillin and
gentamicin treatment of Pseudomonas aeruginosa infection in
patients with cystic fibrosis. Lancet 1981;2(8256):1137–9.
w6x Hodson ME. Maintenance treatment with antibiotics in cystic
fibrosis patients, sense or nonsense? Netherlands J Med
1995;46:288–92.
w7x Hodson ME, Gallagher CG, Govan JRW. A randomised clinical
trial of nebulised tobramycin or colistin in cystic fibrosis. Eur
Respir J 2002;20:658–64.
w8x Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes
in the normal maximal expiratory flow-volume curve with
growth and aging. Am Rev Respir Dis 1983;127(6):725–34.
w9x Freeman JV, Cole TJ, Chinn S, Jones PRM, White EM, Preece
MA. Cross-sectional stature and weight reference curves for
the UK 1990. Arch Dis Child 1995;73:17–24.
w10x NHS Reference Costs and Trust Finance Returns, 2001, at
http:yywww.doh.gov.ukynhsexecyrefcosts.htm.
w11x Carpenter J, Bithell J. Bootstrap confidence intervals: when,
which, what? A practical guide for medical statisticians. Stat
Med 2000;19:1141–64.
w12x Efron B. Better bootstrap confidence intervals. J Am Stat
Assoc 1987;82:171–200.
w13x Barber JA, Thompson SG. Analysis and interpretation of cost
data in randomised controlled trials: review of published
studies. Br Med J 1998;317:1195–200.
w14x Moss RB. Administration of aerosolised antibiotics in cystic
fibrosis patients. Chest 2001;120:107S–113S.
w15x Cystic Fibrosis Trust, Antibiotic treatment for cystic fibrosis.
Report of the UK Cystic Fibrosis Trust’s Antibiotic Group.
April 2000.
w16x Kerem E, Reisman J, Corey M, Canny GJ, Levison H.
Prediction of mortality in patients with cystic fibrosis. N Engl
J Med 1992;326:1187–91.
w17x Warner JO. Review of prescribed treatment for children with
asthma in 1990. BMJ 1995;311:663–6.
w18x Ievers CE, Brown RT, Drotar D, Caplan D, Pishevar BS,
Lambert RG. Knowledge of physician prescriptions and adher-
ence to treatment among children with cystic fibrosis and their
mothers. Dev Behav Pediatr 1999;20(5):335–43.
w19x Robson M, Abbott J, Webb K, Dodd M, Walsworth-Bell J. A
cost description of an adult cystic fibrosis unit and cost analyses
of different categories of patients. Thorax 1992;47:684–9.
w20x Wildhagen MF, Verheij JBGM, Hilderink HBM, Kooij L,
Tijmstra T, ten Kate LP, Gerritsen J, Bakker W, Habbema JD,
Habbema F. Cost of care of patients in The Netherlands in
1990–1991. Thorax 1996;51:298–301.
w21x Littlewood JM, Cross E. Present day treatment of cystic
fibrosis: its content and cost. In clinical economics in gastro-
enterology. Oxford: Blackwell Science, 2000.
w22x Packe GE, Hodson ME. Changes in spirometry during consec-
utive admissions for infective pulmonary exacerbations in
adolescent and adult cystic fibrosis. Respir Med January
1992;86(1):45–8.
w23x Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent
pulmonary exacerbations on quality of life in patients with
cystic fibrosis. Chest 2002;121(1):64–72.
w24x Moss RB. Long-term benefits of inhaled tobramycin in adoles-
cent patients with cystic fibrosis. Chest 2002;121(1):55–63.
w25x de Jong PA, Nakano Y, Lequin MH, Woods RPDP, Tiddens
HAWM. High resolution CT scans show progressive structural
abnormalities in the presence of stable pulmonary function
tests in children with cystic fibrosis. J Cystic Fibrosis
2002;1:s66.
